Polaris Partners: The 2013 A-List Investor Spotlight
This article was originally published in Start Up
Polaris’ focus on people and platforms was never more evident than in 2013, when it leveraged its relationship with one entrepreneur in particular to great effect.
You may also be interested in...
Avitide Rolls Out Series A to Launch Biologics Purification Co.
Avitide Inc. raised an undisclosed Series A financing from a strong and familiar syndicate to provide custom affinity purification solutions to biologics manufacturers.
deCODE Re-Emerges: Can a Genomics Platform Model Work in Diagnostics?
deCODE Genetics has emerged from bankruptcy with a streamlined, diagnostics-oriented business model. In the near term, the privately held firm expects to offer its genomics discovery capabilities on a service basis, echoing the original genomics platform specialists of the late 1990s, including deCODE itself, which did largely unsuccessful technology deals focused on using genetic insight to generate therapies. The difference? It is now using genetic information to assess disease risk and better manage patient health, a strategy it thinks will succeed as the field of personalized medicine diagnostics continues to gain traction.
Embracing Early-Stage Platform Opportunities at Polaris Ventures
In an interview with START-UP, Polaris Ventures managing partner Terry McGuire discusses recent investment opportunities and his firm's approach to platform technologies in the life sciences. Topics covered include: diagnostics, community diseases, next-generation biologics, and fund diversification.